| Title |
Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients
|
|---|---|
| Published in |
Clinical Interventions in Aging, September 2012
|
| DOI | 10.2147/cia.s14566 |
| Pubmed ID | |
| Authors |
Andrew J Yee, Noopur S Raje |
| Abstract |
Bone loss is a common side effect of cancer treatments, especially antihormonal treatments used in the treatment of breast and prostate cancer. Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand. It is effective in settings ranging from preventing skeletal-related complications in cancer patients with metastatic disease to increasing bone mineral density in patients with osteoporosis. In cancer patients with early stage disease, denosumab can attenuate bone loss from antihormonal treatments, and in prostate cancer, may reduce disease progression. Here, we will discuss the important role denosumab may play in the management of bone loss in patients with cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 1% |
| Italy | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 70 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 14 | 19% |
| Student > Master | 11 | 15% |
| Student > Doctoral Student | 7 | 10% |
| Researcher | 6 | 8% |
| Student > Ph. D. Student | 6 | 8% |
| Other | 14 | 19% |
| Unknown | 15 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 43 | 59% |
| Agricultural and Biological Sciences | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Unspecified | 1 | 1% |
| Mathematics | 1 | 1% |
| Other | 6 | 8% |
| Unknown | 13 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 September 2012.
All research outputs
#20,110,957
of 25,584,565 outputs
Outputs from Clinical Interventions in Aging
#1,393
of 1,962 outputs
Outputs of similar age
#143,349
of 188,508 outputs
Outputs of similar age from Clinical Interventions in Aging
#6
of 8 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,962 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,508 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.